Search This Blog

Wednesday, July 28, 2021

Bluebird Bio, Resilience to Develop Next Gen Cell Therapies

 Resilience to acquire bluebird’s clinical and commercial suspension lentiviral vector manufacturing facility in North Carolina, retaining all current employees at the site

Alliance designed to foster best in class cell therapy product and manufacturing innovation through risk-sharing and royalty-based model

bluebird to receive $110M upfront, preferred LVV manufacturing access and significantly reduce operational expenses over coming years

https://finance.yahoo.com/news/bluebird-bio-resilience-announce-strategic-120000678.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.